The stock's rise snapped a four-day losing streak.

Vertex Pharmaceuticals (NASDAQ:VRTX) announced Friday that an expert panel of the EU drug regulator, the European Medicines ...

BMO Capital analyst Daniel Jester lowered the firm’s price target on Vertex (VERX) to $41 from $56 and keeps a Market Perform rating on the ...

DA Davidson analyst William Jellison lowered the firm’s price target on Vertex (VERX) to $55 from $62 and keeps a Buy rating on the shares.

Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeuti | Vertex has backed out of its in vivo ...

Rob Sechan, CEO of NewEdge Wealth, joins CNBC's "Halftime Report" to detail his many portfolio moves.

Vertex Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, today announced the ...

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...

Verve offered few details on the early end of a collaboration the companies inked in 2022, saying only that Vertex cited “changing priorities.” ...

Arc’teryx unveils its 2025 footwear lineup, featuring the Norvan LD 4, Vertex Speed, and Konseal, designed to enhance ...

It's not enough to go far or even fast. The upcoming Arc'teryx Vertex Speed trail running shoe can also travel high.

Arc'teryx’s new footwear models will be available globally, launching throughout 2025. The Norvan LD 4 arrives in March, ...